View:
-------------------------------------------
OMB APPROVAL
-------------------------------------------
OMB Number:
Expires:
Estimated average burden
hours per form...................
-------------------------------------------
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D/A
Under the Securities Exchange Act of 1934
(Amendment No. 1)*
Healthcore Medical Solutions, Inc.
- --------------------------------------------------------------------------------
(Name of Issuer)
Class A Common Stock
- --------------------------------------------------------------------------------
(Title of Class of Securities)
42220B101
- --------------------------------------------------------------------------------
(CUSIP Number)
Adam D. Eilenberg
Ehrenreich Eilenberg Krause & Zivian LLP
11 East 44th Street, 17th Floor
New York, N.Y. 10017
(212) 986-9700
- --------------------------------------------------------------------------------
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
January 6, 1999
- --------------------------------------------------------------------------------
(Date of Event which Requires Filing
of this Statement)
If the filing person has previously filed a statement of Schedule 13G to report
the acquisition which is the subject of the Schedule 13D, and is filing this
schedule because of Rule 13d-1(b)(3) or (4), check the following box [ ].
Note: Six copies of this statement, including all exhibits, should be filed with
the Commission. See Rule 13d-1(a) for other parties to whom copies are to be
sent.
*The remainder of this cover page shall be filed out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
(Continued on following page(s))
CUSIP No. 42220B101 13D
- --------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
SIGA Pharmaceuticals, Inc.
- --------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) [ ]
(b) [ ]
- --------------------------------------------------------------------------------
3 SEC USE ONLY
- --------------------------------------------------------------------------------
4 SOURCE OF FUNDS*
WC
- --------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
ITEMS 2(d) OR 2(e) [ ]
- --------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
DE
- --------------------------------------------------------------------------------
7 SOLE VOTING POWER
NUMBER OF 300,800 (including 149,800 Warrants
SHARES exercisable at $6.50 per share)
BENEFICIALLY --------------------------------------------------------------
OWNED BY 8 SHARED VOTING POWER
EACH 0
REPORTING --------------------------------------------------------------
PERSON 9 SOLE DISPOSITIVE POWER
WITH 300,800 (including 149,800 Warrants
exercisable at $6.50 per share)
--------------------------------------------------------------
10 SHARED DISPOSITIVE POWER
0
- --------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
300,800 (including 149,800 Warrants exercisable at $6.50 per share)
- --------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*
[ ]
- --------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
5.003% (taking into account only shares of Common Stock; 9.50% if also
including 149,800 Warrants exercisable at $6.50 per share)
- --------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
CO
- --------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
CUSIP No. 42220B101 13D
Schedule 13D
Item 1. Security and Issuer
This statement relates to the Class A Common Stock, $.01 par value ("Common
Stock"), of Healthcore Medical Solutions, Inc. (the "Issuer"), which has its
principal executive office at 11904 Blue Ridge Boulevard, Grandview, MO 64030.
This statement is filed pursuant to Rule 13d-2(a) with respect to securities
owned by the reporting person specified herein as of January 11, 1999 and amends
the Schedule 13 D filed on October 15, 1998 (the "Schedule 13D"). Except as set
forth herein, the Schedule 13D is hereby restated in its entirety.
Item 4. Purpose of Transaction
The Reporting Person acquired the shares of Common Stock and the Units for
investment purposes. After a meeting with the Chairman of the Board of the
Issuer and several discussions, the Reporting Person on January 6, 1999 sent a
letter to the Chairman of the Board suggesting a possible combination of the
Issuer and the Reporting Person and outlining the terms of a possible share
exchange transaction. The Reporting Person also sought the Chairman's reactions
to such outline. No formal offer was made by the Reporting Person to acquire the
Issuer.
While the Reporting Person has no present intention to purchase any additional
shares of Common Stock or Units, it may, depending upon its evaluation of the
Issuer's business and prospects, determine to increase or decrease or dispose of
its position in the Issuer. In making any such determination, the Reporting
Person will also take into consideration other available business opportunities
and general economic conditions.
Signature
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
Date: January 11, 1999
SIGA PHARMACEUTICALS, INC.
By: /s/ JUDSON A. COOPER
----------------------------------
Name: Judson A. Cooper
Title: Chairman of the Board